Basel, 21 May 2018 Roche’s Hemlibra reduced treated bleeds by 96 percent compared to no prophylaxis in phase III HAVEN 3 study in haemophilia A without factor VIII inhibitors In a subset of patients in the HAVEN 3 study who previously received factor VIII prophylaxis, the standard of care, Hemlibra reduced bleeds by 68 percent... Read more
Basel, 17 May 2018 Follow-up phase III data showed Roche’s Alecensa helped people with ALK-positive metastatic non-small cell lung cancer live a median of almost three years without their disease worsening or death Investigator-assessed longer follow-up of the ALEX study demonstrated sustained benefit in the reduction of the risk of disease progression or death (57%)... Read more
Basel, 17 May 2018 Phase III IMpower150 study showed Roche’s Tecentriq and Avastin plus carboplatin and paclitaxel helped people with a specific type of metastatic lung cancer live significantly longer compared to Avastin plus carboplatin and paclitaxel A survival advantage for the Tecentriq and Avastin combination regimen was observed in all pre-specified exploratory patient subgroups... Read more
Thermo Fisher Scientific Installs First Glacios Cryo-Electron Microscope for Drug Discovery and Development Breakthrough platform optimizes productivity and expands cryo-EM entry path for a broader range of researchers HILLSBORO, Ore., May 16, 2018 /PRNewswire/ — Thermo Fisher Scientific, the world leader in serving science, today announced Astex Pharmaceuticals, a leader in innovative drug discovery and development,... Read more
Mailing addressesCorrespondence should be mailed to:ComputershareP.O. Box 505000Louisville, KY 40233 Overnight correspondence should be sent to:Computershare462 South 4th Street, Suite 1600Louisville, KY 40202 Shareholder website www.computershare.com/investorShareholder online inquirieswww-us.computershare.com/investor/Contact Read more
Complete and easy-to-use LC-MS-based solution for biotherapeutics characterization and quality testing May 14, 2018 Framingham, MA — SCIEX, a global leader in life science analytical technologies, today announced the newly released BioPharmaView™ Software 3.0 solution for the complete LC-MS Multiple Attribute Methodology (MAM) Workflow, that enables simple yet in-depth characterization of biologics through powerful mass spectrometry.... Read more
Basel, 14 May 2018 Roche to present new phase III data for Hemlibra in people with haemophilia A at the World Federation of Hemophilia 2018 World Congress Data include results from HAVEN 3 study in people with haemophilia A without factor VIII inhibitors and HAVEN 4 study in people with haemophilia A with or without... Read more
Basel, 14 May 2018 Roche to present new phase III data for Hemlibra in people with haemophilia A at the World Federation of Hemophilia 2018 World Congress Data include results from HAVEN 3 study in people with haemophilia A without factor VIII inhibitors and HAVEN 4 study in people with haemophilia A with or without... Read more
Basel, 10 May 2018 Roche provides update on Phase III study of Tecentriq (atezolizumab) and Cotellic (cobimetinib) in people with heavily pre-treated locally advanced or metastatic colorectal cancer Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the Phase III IMblaze370 study evaluating the combination of Tecentriq® (atezolizumab) and Cotellic® (cobimetinib) did not meet its... Read more
Basel, 10 May 2018 Roche provides update on Phase III study of Tecentriq (atezolizumab) and Cotellic (cobimetinib) in people with heavily pre-treated locally advanced or metastatic colorectal cancer Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the Phase III IMblaze370 study evaluating the combination of Tecentriq® (atezolizumab) and Cotellic® (cobimetinib) did not meet its... Read more